ACA
VKTX icon

Avoro Capital Advisors’s Viking Therapeutics VKTX Stock Holding History

Avoro Capital Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,590,000
Closed -$294M – 46
2024
Q1 		$294M Buy
+3,590,000
New +$160M 3.43% 12
2018
Q3 		– Sell
-4,471,300
Closed -$42.4M – 47
2018
Q2 		$42.4M Buy
+4,471,300
New +$29.7M 1.63% 21

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Avoro Capital Advisors's VKTX Position: Q2 2024 in Review

Avoro Capital Advisors sold out of Viking Therapeutics (VKTX) in Q2 2024, closing a stake of 3,590,000 shares — an estimated $294M sold.

Avoro Capital Advisors first reported a position in VKTX in Q2 2018 and held it in 2 quarters. The position peaked at $294M in Q1 2024. 387 funds tracked by Wall St. Rank hold VKTX as of Q2 2024.

  • Avoro Capital Advisors reported no remaining Viking Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Avoro Capital Advisors sold 3,590,000 Viking Therapeutics shares in Q2 2024, an estimated $294M.
  • Avoro Capital Advisors first reported a position in Viking Therapeutics in Q2 2018 and held it in 2 quarters.
  • Avoro Capital Advisors's Viking Therapeutics position peaked at $294M in Q1 2024.
  • 387 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2024.

Based on Avoro Capital Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.